Page Title
Drug Development Pipeline
Back to the Drug Development Pipeline
Reata Pharmaceuticals
Status
Pre-clinicalTherapeutic Approach
Restore CFTR Protein
This program is working to expand the number of therapies designed to fix the defective CFTR protein in people who have the F508del mutation.
Status
Laboratory studies to develop and test these compounds are underway.
Sponsor
This program is sponsored by Reata Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More